Atara Biotherapeutics, Inc. (NASDAQ: ATRA) is a Healthcare company (Biotechnology) with a market capitalization of $66M. The Maz Rating grades it against the other companies in its sector.
Atara Biotherapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $6.50, Atara Biotherapeutics, Inc. trades at 16.7x sales. Over the last twelve months it generated about $4M of revenue and a net loss of $10M. It runs a gross margin of 82.7%, an operating margin of -343.6% and a net margin of -368.6%. It shows return on equity of 38.8%, return on invested capital of -103.8% and a free cash flow yield of -19.6%. On the balance sheet: a debt-to-equity ratio of -0.25 and a current ratio of 1.72. Over the past 52 weeks the share price ranged from $3.92 to $19.15, with a beta of 0.09.
Atara Biotherapeutics, Inc. does not currently pay a dividend.
13 Wall Street analyst ratings cover the stock: 4 Buy, 7 Hold and 2 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as well as various hematologic and solid tumors, such as nasopharyngeal carcinoma. The company is also advancing a robust pipeline of next-generation CAR T immunotherapies designed to combat hematologic malignancies and solid tumors. This includes ATA2271 and ATA3271 targeting mesothelin, alongside ATA2431 and ATA3219 for B-cell malignancies. Furthermore, Atara is developing ATA188 for the treatment of multiple sclerosis and the ATA368 program specifically for cancers associated with human papillomavirus (HPV). To bolster its research and development efforts, Atara Biotherapeutics has established significant collaborations and licensing agreements. These include a licensing partnership with Memorial Sloan Kettering Cancer Center, a license and R&D collaboration with QIMR Berghofer Medical Research Institute, and a strategic alliance with H. Lee Moffitt Cancer Center. Additionally, the company holds a strategic partnership with Bayer AG focused on mesothelin-targeted CAR T-cell therapies for solid tumors.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Atara Biotherapeutics, Inc. (ATRA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 7.37% / 30% · Interest income / Revenue 61.3% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 7.37% / 33% · Receivables / Mkt Cap (36m) 0.51% / 49% · Interest income / Revenue 61.3% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 7.37% / 33.33% · Receivables / Mkt Cap (24m) 0.51% / 33.33% · Interest income / Revenue 61.3% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 65.8% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 45.9% / 33.33% · Receivables / Avg Assets (4Q) 2.83% / 33.33% · Interest income / Revenue 61.3% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 53.3% / 33.33% · (Cash+Recv) / Total Assets 57.0% / 33.33% · Interest income / Revenue 61.3% / 5% | Fail |
No. As of September 2026, Atara Biotherapeutics, Inc. (ATRA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Atara Biotherapeutics, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 61.3% of each dividend: Atara Biotherapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.